6 | sodium-iodide symporter (sodium iodide symporter)IBA
03/2013
-
07/2004 |
5 | AcidsIBA
01/2021
-
07/2004 |
5 | LuciferasesIBA
08/2012
-
07/2004 |
4 | Trastuzumab (Herceptin)FDA Link
01/2021
-
01/2018 |
4 | Radioisotopes (Radionuclides)IBA
03/2013
-
07/2007 |
3 | Proteins (Proteins, Gene)FDA Link
08/2022
-
06/2007 |
3 | CarbohydratesIBA
06/2022
-
01/2022 |
3 | Antihypertensive Agents (Antihypertensives)IBA
01/2022
-
06/2020 |
3 | Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
02/2021
-
06/2020 |
3 | Angiotensin Receptor AntagonistsIBA
02/2021
-
06/2020 |
3 | 1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA
01/2021
-
01/2019 |
3 | Glucose (Dextrose)FDA LinkGeneric
01/2021
-
10/2013 |
3 | RNA (Ribonucleic Acid)IBA
02/2020
-
04/2016 |
3 | Thymidine KinaseIBA
02/2020
-
11/2010 |
3 | Biomarkers (Surrogate Marker)IBA
10/2019
-
01/2018 |
3 | Cetuximab (Erbitux)FDA Link
10/2018
-
01/2016 |
3 | Therapeutic UsesIBA
02/2015
-
07/2007 |
2 | DiureticsIBA
01/2022
-
02/2021 |
2 | Blood Glucose (Blood Sugar)IBA
12/2021
-
11/2019 |
2 | Calcium Channel Blockers (Blockers, Calcium Channel)IBA
02/2021
-
06/2020 |
2 | Telomerase (Telomerase Reverse Transcriptase)IBA
02/2020
-
09/2008 |
2 | Chelating AgentsIBA
10/2019
-
01/2016 |
2 | ErbB Receptors (EGF Receptor)IBA
10/2018
-
11/2017 |
2 | RadiopharmaceuticalsIBA
11/2017
-
01/2016 |
2 | alpha-Fetoproteins (alpha-Fetoprotein)IBA
07/2016
-
03/2013 |
2 | Pharmaceutical PreparationsIBA
07/2016
-
10/2013 |
2 | Firefly LuciferasesIBA
06/2016
-
09/2010 |
2 | Ganciclovir (Cytovene)FDA LinkGeneric
02/2015
-
11/2010 |
2 | Fetal Proteins (Fetoprotein)IBA
02/2015
-
08/2012 |
2 | Diethylnitrosamine (N-Nitrosodiethylamine)IBA
01/2015
-
08/2012 |
2 | Hepatitis B Core AntigensIBA
07/2013
-
06/2008 |
2 | Doxorubicin (Adriamycin)FDA LinkGeneric
09/2007
-
12/2004 |
1 | AdenineFDA LinkGeneric
08/2022 |
1 | Caspase 8 (Caspase-8)IBA
08/2022 |
1 | Caspase 3 (Caspase-3)IBA
08/2022 |
1 | DNA (Deoxyribonucleic Acid)IBA
08/2022 |
1 | Streptozocin (Streptozotocin)FDA Link
12/2021 |
1 | 64Cu-DOTA-rituximabIBA
05/2021 |
1 | Fibronectins (Fibronectin)IBA
04/2021 |
1 | human ERBB2 proteinIBA
01/2021 |
1 | Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2021 |
1 | Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2021 |
1 | omega-Chloroacetophenone (Mace)IBA
01/2021 |
1 | CholesterolIBA
01/2021 |
1 | AntigensIBA
12/2020 |
1 | VaccinesIBA
12/2020 |
1 | Inactivated VaccinesIBA
12/2020 |
1 | Catalytic RNA (Ribozymes)IBA
02/2020 |
1 | Antineoplastic Agents (Antineoplastics)IBA
02/2020 |
1 | ThymidineIBA
02/2020 |
1 | Messenger RNA (mRNA)IBA
11/2019 |
1 | Fatty Acid-Binding ProteinsIBA
11/2019 |
1 | Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA
10/2019 |
1 | AntibodiesIBA
10/2019 |
1 | Paclitaxel (Taxol)FDA LinkGeneric
04/2019 |
1 | Insulin (Novolin)FDA Link
06/2018 |
1 | Deoxyglucose (2 Deoxy D glucose)IBA
11/2017 |
1 | ChitosanIBA
09/2017 |
1 | HydrogelsIBA
09/2017 |
1 | CarcinogensIBA
07/2016 |
1 | Growth Factor ReceptorsIBA
01/2016 |
1 | Peptide Receptors (Peptide Receptor)IBA
03/2015 |
1 | 1- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononaneIBA
03/2015 |
1 | Acetic Acid (Vinegar)FDA LinkGeneric
03/2015 |